Notice bibliographique
Résumé
Dear Sir, The recent global outbreak of MPOX has underscored the urgent need for effective countermeasures, including vaccines. While significant progress has been made in vaccine development, several critical factors must be carefully considered to ensure their efficacy and equitable distribution. The currently existing MPOX Vaccines like, Jynneos (Bavarix), this FDA-approved vaccine is primarily used for smallpox prevention, but has also been shown to be effective against MPOX in animal studies.[1] It is a two-dose vaccine administered subcutaneously. Imvanix that is approved in the European Union and Canada for smallpox prevention. It is a single-dose vaccine administered intradermally.[2] Acambis is being developed by Bavarian Nordic and is currently undergoing clinical trials. It is a single-dose vaccine administered intradermally and Vaccinia Ankara (VACV-Ankara) is being developed by various research groups and is currently in preclinical development. It is a single-dose vaccine administered intramuscularly.[3] We do have some challenges and considerations though like efficacy and safety. While initial studies have shown promising results, it is imperative to conduct rigorous clinical trials to evaluate the long-term efficacy of MPOX vaccines. This includes assessing their durability over time and identifying potential waning immunity and safety profile. It is crucial to monitor for potential side effects and adverse reactions associated with MPOX vaccines. This includes short-term and long-term safety assessments. Also, the emergence of new MPOX variants could potentially compromise vaccine effectiveness. Ongoing research is essential to monitor viral evolution and adapt vaccine formulations as needed.[4] Production and distribution are also very crucial and scaling up vaccine production to meet global demand presents significant logistical challenges. Investing in manufacturing facilities, ensuring access to essential raw materials, and addressing potential bottlenecks in the supply chain are critical for ensuring adequate supply. Ensuring equitable distribution of MPOX vaccines, particularly to low- and middle-income countries, is essential for global health security. International collaboration, support for vaccine affordability, and addressing vaccine hesitancy are crucial to address this issue.[5] Public Health Measures are important for surveillance as they are essential for early detection and timely response to future MPOX outbreaks. This includes investing in diagnostic testing, contact tracing capabilities, and data analysis. Promoting education and awareness about MPOX transmission, risk reduction behaviors, and vaccination is crucial for preventing future outbreaks. This includes targeted messaging for at-risk populations, providing access to preventive resources, and addressing vaccine hesitancy. Ensuring adequate healthcare capacity to manage MPOX cases and provide supportive care is essential for mitigating the impact of outbreaks. This includes training healthcare workers, establishing isolation facilities, and ensuring access to essential medical supplies.[6] Ethical considerations should be considered in determining who should receive the vaccine first in the event of limited supply raises ethical questions. Factors such as age, occupation, health status, and risk of exposure should be considered when developing prioritization guidelines. Also, ensuring informed consent from vaccine recipients is essential for ethical vaccine administration. This involves providing clear information about the benefits, risks, and alternatives to vaccination.[7] CONCLUSION The development of Monkeypox virus (MPOX) vaccines represent a significant milestone in combating this infectious disease. However, it is essential to approach this endeavor with a balanced perspective, recognizing the challenges and limitations involved. By investing in research, production, and public health measures, we can effectively mitigate the threat of MPOX and protect global health. Data availability statement All the refrences are the source of data. Author contribution Conceptualization of the study by Isha Sangtani, writing original draft and editing done by Isha Sangtani and Shahzad Mirza. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,019 | 0,034 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,002 | 0,001 |
| Bibliométrie | 0,002 | 0,001 |
| Études des sciences et des technologies | 0,001 | 0,003 |
| Communication savante | 0,006 | 0,014 |
| Science ouverte | 0,003 | 0,003 |
| Intégrité de la recherche | 0,010 | 0,016 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,013 | 0,004 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».